| Jun 24 | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 124.67K | $ 161.16K | $ 125.05K | $ 91.98K | AU$ 145.90K |
| Gross Profit | $ 21.72K | $ -89.31K | $ -107.42K | $ -480.00K | AU$ -371.37K |
| Operating Income | $ -191.84M | $ -223.45M | $ -133.27M | $ -53.18M | AU$ -24.70M |
| EBITDA | $ -200.02M | $ -223.30M | $ -99.01M | $ -50.14M | AU$ -24.92M |
| Net Income | $ -220.24M | $ -211.88M | $ -127.99M | $ -60.79M | AU$ -16.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 172.47M | $ 133.99M | $ 64.90M | $ 157.43M | AU$ 62.02M |
| Total Assets | $ 188.79M | $ 148.19M | $ 87.32M | $ 184.36M | AU$ 71.89M |
| Total Debt | $ 141.65M | $ 272.98K | $ 0.00 | $ 150.47K | AU$ 265.08K |
| Net Debt | $ -30.82M | $ -133.71M | $ -64.90M | $ -157.28M | AU$ -61.76M |
| Total Liabilities | $ 264.60M | $ 156.98M | $ 17.55M | $ 4.16M | AU$ 7.08M |
| Stockholders' Equity | $ -75.81M | $ -8.79M | $ 69.77M | $ 180.20M | AU$ 64.81M |
| Cash Flow | |||||
| Free Cash Flow | $ -161.05M | $ -179.34M | $ -98.39M | $ -61.08M | - |
| Operating Cash Flow | $ -161.02M | $ -179.30M | $ -98.37M | $ -61.06M | AU$ -8.24M |
| Investing Cash Flow | $ -33.49K | $ -32.64K | $ -23.32K | $ 880.07K | AU$ 482.83K |
| Financing Cash Flow | $ 243.73M | $ 248.70M | $ 236.62K | $ 156.76M | AU$ 48.06M |
Ceryvyn Therapeutics Limited (DE:UKJ2)
MUNICH:UKJ2
